Want to see FR:ALMIB full AI Analyst Report?
Top Page
Amoeba SA
(ALMIB)
Select Model
Select Model
Rating:41Neutral
Price Target:
€0.55
▼(-19.41% Downside)
Action:Reiterated
Date:09/10/26
The score is driven primarily by very weak financial performance, including collapsed revenue, persistent losses, ongoing cash burn, and negative equity with rising debt. Technicals add further pressure with a clear downtrend (price below all key moving averages) despite oversold readings. Valuation is limited by a negative P/E and no dividend support.
Positive Factors
Biological alternatives platform
A platform based on a naturally occurring organism gives Amoéba a differentiated foundation in biological crop protection and plant health. If regulatory and commercial execution progress, this positioning could support durable relevance as agriculture seeks alternatives to conventional chemical inputs.
Negative Factors
Revenue collapse
Revenue collapsing to zero demonstrates that the company has not yet established dependable commercial scale. Without recurring sales, Amoéba has limited operating leverage and cannot sustainably fund development from customers, making future performance highly dependent on successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Biological alternatives platform
A platform based on a naturally occurring organism gives Amoéba a differentiated foundation in biological crop protection and plant health. If regulatory and commercial execution progress, this positioning could support durable relevance as agriculture seeks alternatives to conventional chemical inputs.
Read all positive factors
Amoeba SA (ALMIB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€45.27M
Dividend YieldN/A
Average Volume (3M)211.34K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue GrowthN/A
EPS Growth-2.77%
CountryFR
Employees23
SectorGeneral
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume336,065
30 Day Avg. Volume211,342
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Amoeba SA Business Overview & Revenue Model
Company Description
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying acr...
How the Company Makes Money
Amoéba makes money by developing, manufacturing (directly and/or via industrialization partners), and selling biological products derived from its Willaertia magna platform, primarily into agriculture. Key revenue streams include: (1) Sales of bio...
Amoeba SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 601.60K | 664.31K | 0.00 | 0.00 |
| Gross Profit | -2.57M | -805.57K | -1.71M | -1.01M | -858.95K |
| EBITDA | -7.20M | -5.38M | -13.74M | -5.35M | -5.01M |
| Net Income | -8.30M | -6.59M | -14.30M | -8.02M | -7.82M |
Balance Sheet | |||||
| Total Assets | 10.13M | 5.65M | 6.29M | 12.39M | 14.50M |
| Cash, Cash Equivalents and Short-Term Investments | 4.72M | 458.94K | 519.33K | 5.53M | 7.28M |
| Total Debt | 12.24M | 12.07M | 4.92M | 2.36M | 12.50M |
| Total Liabilities | 15.49M | 16.06M | 10.23M | 4.23M | 14.30M |
| Stockholders Equity | -5.36M | -10.41M | -3.94M | 8.16M | 213.68K |
Cash Flow | |||||
| Free Cash Flow | -7.42M | -4.78M | -12.59M | -5.71M | -6.05M |
| Operating Cash Flow | -6.13M | -4.22M | -6.50M | -5.40M | -5.90M |
| Investing Cash Flow | -1.30M | -2.01M | -2.81M | -212.13K | -140.65K |
| Financing Cash Flow | 11.69M | 6.16M | 4.30M | 3.87M | 4.98M |
Amoeba SA Technical Analysis
Negative
0.68
Price Trends
0.70
Negative
0.77
Negative
0.86
Negative
Market Momentum
-0.03
Positive
24.67
Positive
14.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMIB, the sentiment is Negative. The current price of 0.68 is above the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.70, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 24.67 is Positive, neither overbought nor oversold. The STOCH value of 14.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMIB.
Amoeba SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €54.13M | 17.74 | 13.43% | 0.84% | 8.98% | -11.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €73.90M | -9.64 | -101.20% | ― | 66.67% | 74.66% | |
41 Neutral | €45.27M | -4.79 | 84.60% | ― | ― | -2.77% | |
39 Underperform | €2.54M | -0.99 | -1.63% | 2.07% | -4.08% | -112.93% | |
32 Underperform | €37.43M | -1.30 | -59.61% | 8.69% | ― | ― |
* General Sector Average
FR:ALMIB
Amoeba SA
0.58
-0.37
-39.01%
FR:ALJXR
Archos
0.28
0.07
31.46%
FR:ALATA
Atari SA
19.76
-10.54
-34.79%
FR:ALCLA
Claranova SA
0.65
-1.05
-61.81%
FR:BIG
Bigben Interactive
0.14
-1.24
-90.09%
FR:COH
Coheris
9.58
0.58
6.42%
Amoeba SA Corporate Events
Amoéba and Koppert Extend Biofungicide Distribution Deal to 2031
Jul 23, 2026
Amoéba SA and its partner Koppert, a global leader in biological crop protection, have extended their distribution agreement for the biofungicide solution targeting vines and vegetable crops by one year, pushing the term to June 2031. The par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.